Articles tagged with Parkinsons Disease
A device called VibeForward reduces symptoms of freezing of gait in patients with Parkinson's disease by providing vibration therapy through a portable, non-invasive shoe. The technology has shown early evidence to help improve daily life for those with the condition.
A lab study found that a substance called Emapunil alleviated motor disorders in mice, potentially slowing down Parkinson's disease progression. The compound targets microglia and TSPO, a molecular receptor involved in neurodegeneration.
Researchers tested an experimental treatment boosting Glial Cell Line Derived Neurotrophic Factor (GDNF) to regenerate dopamine brain cells in patients with Parkinson's. After nine months, the group receiving GDNF showed a 100% improvement in affected brain areas, offering hope for a potential reversal of the condition.
A pioneering clinical trial has shown promising effects on restoring brain cells damaged in Parkinson's. While the treatment did not significantly impact symptoms, it demonstrated significant improvements in brain scans, suggesting long-term beneficial effects may be possible.
A new study finds that Parkinson's disease patients treated with Deep Brain Stimulation (DBS) do not exhibit increased impulsive decision-making when faced with immediate or delayed rewards. The research challenges existing notions about the technique's impact on behavior and cognitive processes.
Using a mouse model of Parkinson's disease, researchers identified unusual patterns of brain activity that appear to underlie its signature symptoms. The striatal neurons' normal pattern of activity warps when dopamine levels are low, leading to synchronized cell firing and repetitive movements.
Scientists at the University of Virginia Health System identified a potential explanation for the death of specific brain cells seen in Alzheimer's and Parkinson's diseases. The discovery suggests that naturally occurring gene variation, called 'somatic mosaicism,' may be responsible for this selective vulnerability.
Recent advances in understanding Parkinson's disease have identified promising developments to slow or stop its progression. Researchers explore new therapeutic targets, targeting non-motor features of the disease, and repurposing drugs for their potential disease-modifying properties.
Researchers at the Buck Institute have identified a novel molecular mechanism that orchestrates harmful inflammatory signaling in glial cells, contributing to Parkinson's disease pathology. Blocking Furin 1, a catalytic protein, in dopaminergic neurons reduces toxic cross-talk and protects neurons from degeneration.
Researchers at Osaka University developed a neurofeedback system allowing Parkinson's patients to control β waves in their deep brain. The system enables voluntary control of beta wave activity, which is associated with symptoms of the disorder.
A new study is analyzing blood samples from over 2,500 participants to identify biomarkers of Parkinson's disease. The researchers aim to find molecular indicators in DNA that can aid in early diagnosis and treatment.
Researchers review novel research hypotheses and approaches to understand the role of environment in Parkinson's disease, particularly before diagnosis. The study suggests targeting specific environmental factors via the nose or gut may help prevent or modify the disease's progression.
Researchers found that gut microbiota can convert levodopa into dopamine, reducing its effectiveness in treating Parkinson's disease. The study suggests that the presence of bacterial tyrosine decarboxylase enzyme contributes to this effect.
Researchers discovered manganese's role in disrupting protein transport, leading to parkinsonian symptoms. Manganese accumulates in cellular vesicles, disturbing nerve cell function and affecting Parkinson's disease-like symptoms.
A study suggests defective astrocytes contribute to α-synuclein accumulation, leading to neuronal degeneration. Researchers discovered that healthy astrocytes can prevent α-synuclein buildup and restore neuronal function when cultured with Parkinson's disease neurons.
Researchers at Clemson University discover Mojave rattlesnakes have a wider distribution of life-threatening venom types than expected. The study reveals a peculiar variability in the species, with local optima favoring different venom types depending on location.
The FDA has approved focused ultrasound treatment for reducing medication-resistant Parkinson's disease tremors, allowing doctors to perform brain surgery without cutting into the skull. Researchers are now exploring its potential for treating other conditions, including breast cancer and epilepsy.
Researchers at Michigan State University have developed a gene therapy that could reduce and possibly eliminate dyskinesia, a frustrating side effect of levodopa treatment in Parkinson's patients. The study focuses on brain cells and has shown promising results in preventing the development of dyskinesia over extended periods.
Researchers found defective astrocytes cause accumulation of toxic alpha-synuclein, leading to neuronal death and degeneration. Healthy astrocytes protect neurons from cell death through restored cellular degradation processes.
A new mouse model has revealed the crucial role of PARL in maintaining mitochondrial respiratory chain function and structural integrity. The study found that mice lacking PARL display symptoms reminiscent of Leigh syndrome, highlighting the importance of understanding the protein's mechanisms in neurodegenerative diseases.
A new neurostimulator, WAND, can stimulate and record electric current in the brain simultaneously, potentially delivering fine-tuned treatments to patients with diseases like epilepsy and Parkinson's. This closed-loop system allows for real-time adjustments, enabling improved outcomes and accessibility.
Scientists at the University of Edinburgh have created stem cells that can transform into brain cells and produce dopamine, a key neurotransmitter lost in Parkinson's. The gene-edited cells resisted developing Lewy bodies, a hallmark of Parkinson's disease.
Researchers have discovered that protein clumps, particularly pα-syn*, recruit enzymes and tau to damage brain cells, leading to mitochondrial destruction. This study provides insight into the molecular mechanisms of Parkinson's disease, shedding light on potential treatment targets.
Researchers have discovered how a protein called Parkin protects neurons in the brain by repairing internal damage that may otherwise kill them. The study found that Parkin 'buys time' for cells to respond to damage and triggers cell death, potentially leading to neuronal loss in Parkinson's disease.
Researchers developed a method to translate brain activity into visual representations, enabling patients to increase or decrease beta waves associated with symptoms. Although no improvement in symptoms was observed, the study demonstrates a new approach toward managing disease-related brain activity that could inform new treatments.
Researchers at Rutgers University discovered that a fatty acid derivative of serotonin in coffee beans' waxy coating, EHT, combined with caffeine can protect against brain degeneration. This combination boosts the activity of a catalyst that prevents protein accumulation associated with Parkinson's disease and Lewy body dementia.
The company's discovery engine identified a series of compounds that shielded cells against alpha-synuclein-induced toxicity by inhibiting stearoyl-CoA desaturase. This finding suggests that inhibition of fatty acid desaturation could be a potential therapeutic approach for treating Parkinson's disease and other synuclein-based disorders.
Researchers found that combining low doses of paraquat herbicide with sugar-binding proteins called lectins triggered Parkinsonism-like symptoms in rats. The study suggests that the toxin travels from the stomach to the brain, forming a misfolded protein alpha-synuclein that causes the disease.
Research reveals that coffee compounds eicosanoyl-5-hydroxytryptamide and caffeine work together to maintain enzyme PP2A activity, dephosphorylating pathogenic α-synuclein proteins. This synergy prevents neurodegeneration and neuroinflammation in Parkinson's disease models.
A Finnish study of 68,800 patients found that hip fracture surgery is associated with a significant risk of surgical complications. Patients with osteoarthritis, Parkinson's disease, and rheumatic diseases are particularly at risk, with 4.6% experiencing complications within three months of surgery.
Scientists have discovered that an emerging Parkinson's gene therapy called AAV2-GAD creates new brain circuits associated with improved motor movement. The therapy has shown therapeutic effects for patients by forming new neural pathways in the brain, connecting the subthalamic nucleus to other motor regions.
Research found that more Oregonians filled out POLST forms between 2015-16, with a 45% increase compared to 2010-11. The study also showed changes in how people use the form, including increased use by middle-aged individuals and those with Alzheimer's and Parkinson's diseases.
A new series of studies assesses death and disability from neurological disorders between 1990 and 2016, finding one in four people worldwide suffered from headaches in 2016. Parkinson's disease has more than doubled since 1990, with motor neuron diseases causing severe disability and high fatality rates.
Researchers at UC Berkeley found that humans rely on two distinct neural networks to predict the future in tasks like music and sports. The basal ganglia system is sensitive to rhythmic cues, while the cerebellum relies on interval timing based on past experiences.
A team of neurologists at Georgetown University Medical Center found that inhibiting the USP13 protein eliminates Lewy bodies and stops their buildup in mouse models of Parkinson's disease. The study suggests targeting USP13 as a therapeutic target for treating Parkinson's and other neurodegenerative diseases.
A new study found that focused ultrasound thalamotomy improves quality of life in people with medication-resistant Parkinson's disease. The procedure showed significant and sustained benefits in functional disability and overall well-being.
Researchers found that singing reduced physiological indicators of stress, improved mood, and enhanced motor symptoms in people with Parkinson's disease. The therapy showed promise as a non-pharmacological approach to manage the condition.
A molecular pathway previously studied in laboratory conditions has been verified to be disrupted in Parkinson's disease patients. The study identifies a key enzyme switch that plays a pivotal role in protecting the brain against stress.
Aryn Gittis, a Carnegie Mellon University neuroscientist, has been recognized for her creativity and originality in research. She discovered a class of neurons that restored movement in a mouse model for Parkinson's disease when targeted with optogenetics.
A recent study suggests that drinking coffee may protect against both Alzheimer's and Parkinson's diseases. The research found that phenylindanes, compounds present in dark roasted coffee, inhibit the formation of beta amyloid and tau protein fragments, which are common in these diseases.
New research presents promising results from preclinical studies using gene therapy to treat amyotrophic lateral sclerosis, Parkinson's disease, and other neurological disorders. Gene therapy has been successfully used to slow disease progression and improve symptoms in mouse models.
A study published in Science identifies Parthanatos as a key driver of nerve cell degradation in Parkinson's disease. The researchers found that blocking a protein called PARP1 can rescue cells from death, suggesting new targets for drugs to interrupt the disease progression.
Researchers at The University of Queensland have developed a promising new therapy using the small molecule MCC950, which blocks NLRP3 activation and prevents brain cell loss in Parkinson's patients. The therapy shows marked improvement in motor function and may offer an alternative approach to current treatments.
A recent study published in Neurology suggests that when Parkinson's disease does not affect thinking skills early on, life span is not affected. The study found people with problems with memory and thinking skills were more likely to die during the study.
A study published in Science Translational Medicine found that removing the appendix early in life can lower the risk of developing Parkinson's disease. The appendix acts as a reservoir for disease-associated proteins, and appendectomy delays disease progression by an average of 3.6 years.
Researchers have developed a novel strategy to measure material properties of the cell nucleus and its components using naturally occurring cellular dynamics. The study shows that human nucleoli behave like liquid droplets, which can influence disease progression, such as Alzheimer's and Parkinson's disease.
Researchers at Lehigh University identify fruit fly protein Scarlet as a key to preventing age-dependent loss of dopaminergic neurons in Parkinson's disease. The study found that Scarlet has a neuroprotective role in a model of the disease, suggesting potential for future treatments.
Researchers tracked over 12,000 participants to estimate the lifetime risk of dementia, Parkinson's disease, and stroke. Preventive strategies could delay onset and reduce lifetime risk by 20-50% in theory, particularly for those aged 85+.
A team of Canadian scientists discovered a French-Canadian founder mutation gene linked to synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease and dementia. The GBA mutation increases the risk of developing these diseases, particularly in people with other mutations.
Researchers evaluated the safety of pimavanserin for treating Parkinson's disease psychosis, finding a lower mortality risk compared to quetiapine or combination therapy. The study provides reassurance for clinicians and families but highlights the need for further research on disease severity and cause of death.
Researchers created a way to measure different types of fear of falling (FOF) in Parkinson's patients, highlighting the importance of cognitive function. The study aims to improve treatment and quality of life for patients with FOF.
A team of scientists has identified a molecule called SynuClean-D that can inhibit the aggregation of alpha-synuclein protein, a key contributor to Parkinson's disease. By administering SynuClean-D to Caenorhabditis elegans worms, researchers were able to reduce alpha-synuclein aggregations and prevent neural degeneration.
Researchers advocate for a systems biology approach to better understand Parkinson's disease, emphasizing the need for modern, human-based technologies to improve treatment outcomes.
A comprehensive study has cataloged over 70,000 novel noncoding RNAs active in dopamine neurons, implicating them in conditions like Parkinson's disease and schizophrenia. The findings suggest that genetic risk variants may affect gene switches in these specialized cells.
Computer simulation models how toxic proteins spread through the brain to reproduce patterns of atrophy associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. The model reveals that biochemistry and connectivity play key roles in mediating disease progression.
MIT neuroscientists have developed tiny probes that can measure dopamine levels in the brain for more than a year. The sensors were implanted in animals and found to produce accurate readings for up to 393 days, opening up new possibilities for understanding dopamine's role in diseases such as Parkinson's.
Researchers found ADHD patients had a higher risk of developing Parkinson's and Parkinson-like diseases than non-ADHD individuals, especially those prescribed stimulant medications. The study suggests that the long-term health effects of ADHD and its treatment remain understudied.
A high-throughput screening study has identified six potent small-molecule inhibitors of α-synuclein aggregation, which could potentially halt Parkinson's disease development. The compounds target the monomeric state of αSN and share a common core structure.
A new €10 million Parkinson's study will implement an integrated care model designed specifically for people with Parkinson's disease across two health hubs in Bath, UK and Nijmegen, Netherlands. The project aims to bridge the gap between fragmented care providers and deliver proactive and integrated care to patients.
Researchers tracked marmosets with Fitbit-like devices to study sleep disturbances, circadian rhythm changes, and cognitive impairment, mirroring Parkinson's non-motor symptoms. The findings provide a valuable animal model for understanding the neuro-circuitry responsible for these complex aspects of the disease.